BioSpace News Archive

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that the Sana Klinikum Offenbach has entered into an agreement to lease and utilize a Senhance® Surgical System.

SLS-002 Was Safe and Well Tolerated Across All Doses with Resolution of Expected Group Mean Dissociative Side-Effects That Occurred in the Higher Dose Groups Within One Hour

Study will evaluate pelareorep’s ability to synergistically combine with the checkpoint inhibitor therapy avelumab and improve outcomes in metastatic breast cancer

With more than half of consumers1 noting they are unhappy with their medical decisions because they lack the right information and guidance, a webinar presentation from two industry leaders will provide both insight and solutions.

ARAZLO™ (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older

Marker Therapeutics, Inc. announced that the United States Adopted Names Council has approved “zelenoleucel” as the nonproprietary name for MT-401, a multi-tumor-associated antigen -specific T cell product candidate for the treatment of patients with acute myeloid leukemia following allogeneic stem cell transplant in both adjuvant and active disease settings.

Salesforce and Siemens announced a strategic partnership to develop a new workplace technology suite that will support businesses globally to safely reopen and deliver the future experience for physical workplaces.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scientific Advisory Board.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it is closing the gap in completing its Investigational New Drug application for its planned clinical trial in locally advanced, inoperable, pancreatic cancer.

Somatus, a market leader in value-based kidney care, announced it has completed a Series C funding round of $64 million.